Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 8, 2025PharmaceuticalsOpen Access

Pharmacogenetic Testing of Children and Adolescents with Mental Health Conditions: Real-World Experiences

View Full Paper
Ask AI
Bookmark
Share

Authors

AKApril KennedySSSierra ScodellaroRVRuud H J Verstegen

Discussion

Loading...

Member takes

Overview

Retrospective analysis highlights limited impact of pharmacogenetic testing on medication dosing in children, suggesting a need for preemptive use.

Key Points

  • PGx testing could have led to dose adjustments for 43% of participants before treatment, indicating its practical implications.
  • Results showed PGx test confirmed only 8% of adverse drug reactions and 3% of treatment inefficacies, highlighting limited validation.
  • Retrospective evaluation studied 100 children and adolescents using psychotropic medications against clinical practice guidelines.
  • Findings suggest PGx testing should be used preemptively to inform treatment decisions rather than in reaction to adverse events.

Cite This Study

Kennedy et al. (2025) studied this question.

synapsesocial.com/papers/68af2b56cf1dd9ea359e414fhttps://doi.org/10.3390/ph18081170
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1561. PHARMACOGENETIC-SUPPORTED PRESCRIBING FOR KIDS WITH MENTAL HEALTH CONDTIONS2025
  2. 2Real‐World Characterization of Psychiatric Pharmacogenomic Test Ordering and Clinical Relevance in Adults and Children2025
  3. 3Evidence level for pharmacogenetic testing in antidepressant treatment: a systematic review2025 · 3 citations
  4. 4A systematic review of real-world evidence on the clinical relevance, characterization, and utility of CYP2D6 biomarker testing2025 · 5 citations
  5. 5177. A GENETICALLY INFORMED APPROACH TO ANTIDEPRESSANT PRESCRIPTION FOR YOUTH WITH MAJOR DEPRESSIVE DISORDER2025